Study Purpose: This study aims to test a new drug, VX-147, to see if it is safe and effective for people with a genetic condition called APOL1-mediated proteinuric kidney disease. This condition affects the kidneys, making them leak protein into the urine.
Eligibility: To join this study, participants need to have a specific genetic makeup (APOL1 genotype of G1/G1, G2/G2, or G1/G2) and have proteinuric kidney disease. People who have had organ transplants, uncontrolled high blood pressure, diabetes, or other known causes of kidney problems cannot participate.
Key Points for Participants:
- The study includes both adults and children, so families can participate together if eligible.
- Participants will be closely monitored for safety, which may require regular visits to the study site.
- Compensation may be provided for participation, but details should be confirmed with the study team.
Important Considerations: Before participating, think about the time commitment and visits required. Discuss any concerns with the study team to understand potential benefits and risks.